Local IGF-1 and Muscle Growth: What the Human Evidence Shows

Insulin-like growth factor 1 (IGF-1) is often discussed as though a blood test can reveal exactly how much muscle a person will build. The biology is more complicated. Skeletal muscle can express local IGF-1 transcripts after exercise, but a short-lived molecular signal is not the same thing as a guaranteed hypertrophy outcome.

This article separates what has been measured in human muscle from what lifters can reasonably do with the information.

Local and circulating IGF-1 are not interchangeable

IGF-1 exists in a system that includes circulating hormone, local muscle production, receptors, binding proteins, and several stages of gene expression and protein processing. A normal or high serum IGF-1 result does not provide a complete readout of local muscle signalling, and a local expression change does not prove that a person will gain more muscle.

A systematic review of resistance training and serum IGF-1 found a pooled increase in some groups, but the studies were highly heterogeneous. That result should not be turned into a blood-test target or a reason to chase growth-hormone or IGF-1 manipulation.

What are IGF-1Ea and MGF?

Human skeletal muscle can express splice variants commonly described as IGF-1Ea and IGF-1Ec, the latter often called mechano growth factor (MGF). A human study comparing young and older adults measured mRNA after a high-resistance knee-extension session. MGF mRNA increased in the younger group in that acute setting, while the older group did not show the same response.

That is useful evidence that age and tissue context may influence gene expression. It does not establish that MGF is a separate “emergency growth signal,” that it peaks on a universal 24–48-hour timetable, or that training a muscle two or three times per week is required to sustain it.

The terminology also needs care. A transcript measured by muscle biopsy is not automatically the same as a functional peptide concentration, receptor activity, or long-term muscle gain. A 2010 review noted that the roles of the different E peptides were still not fully understood.

What resistance training actually tells us

Resistance exercise produces many overlapping signals: mechanical tension, calcium flux, local protein turnover, nervous-system drive, connective-tissue loading, and changes in energy demand. IGF-1-related signalling is one part of that network, not the complete explanation for hypertrophy.

Recent human work examining blood, interstitial fluid, and muscle found that hypertrophy can occur without a simple rise in circulating IGF-1. That is another reason not to use an acute hormone measurement as a score for whether a training programme is working.

Practical implications for lifters

The pathway does not create a special programme:

• use progressive resistance training that you can perform consistently;
• choose load, volume, range, and frequency according to the goal and your recovery;
• eat enough energy and protein for the outcome you want;
• sleep and manage fatigue well enough to repeat quality work; and
• measure performance and body-composition trends rather than chasing a single biomarker.

Do not buy an “MGF” product or research chemical because a content page describes a local growth-factor response. Product identity, purity, legality, anti-doping status, and human safety are separate questions, and unapproved pathway manipulation is not a training recommendation.

The bottom line

Local IGF-1 biology helps explain why muscle responds to mechanical loading, but it is not a simple switch that can be optimised with a fixed rep range, training frequency, supplement, or blood test. The actionable signal is still the repeatable training stimulus and the trend in performance and muscle size over time.

Related reading

• Mechanotransduction: How Muscle Cells Sense Load
• Myostatin and Muscle Growth: What Lifters Can and Cannot Infer

Limits of the evidence

IGF-1 studies measure different compartments, splice transcripts, proteins, time points, ages, and exercise protocols. Acute mRNA or hormone changes are mechanistic evidence, not a personalised hypertrophy prescription or proof that a product is safe.

Sources

• Expression of IGF-I splice variants in young and old human skeletal muscle after high-resistance exercise. Human biopsy study; acute transcript response and age-specific limits.
• IGF-1 E peptides and aging skeletal muscle. Review of local IGF-1 splice variants and unresolved functional questions.
• The effect of resistance training on serum IGF-1. Systematic review and meta-analysis; heterogeneous serum outcomes.
• IGF-1 biocompartmentalization before and after chronic resistance exercise. Human study distinguishing circulating, interstitial, and intramuscular IGF-1.
• Recent advances in human resistance-exercise hypertrophy. Broader review of mechanisms and why acute signals do not replace adaptation outcomes.